Futura's ED treatment gel receives approval in Saudi Arabia

Published: 14-Aug-2023
Distribution Manufacturing Regulatory

Futura Medical's distribution partner Labatec Pharma has received received regulatory approval for MED3000, the gel-based ED treatment, in Saudi Arabia

Pharmaceutical company Futura Medical has announced that its distribution partner Labatec Pharma has received regulatory approval for MED3000, Futura's innovative topical, gel-based Erectile Dysfunction (ED) treatment, in the Kingdom of Saudi Arabia.

Labatec will exclusively launch and commercialise MED3000 under the brand name Eroxon, with initial launch planned in Q4 2023. The manufacturing of Eroxon for the launch has been completed and it will be supported by a full marketing campaign. Saudi Arabia is one of the top ten ED markets in the world by value, with a reported 10.45% of married males experiencing ED.

Labatec will hold a launch symposium showcasing Eroxon at the 20th Urological Association of Asia Congress 2023, which is being held from 28 September to 1 October in conjunction with the 12th Emirates International Urological conference in Dubai, United Arab Emirates.

Regulatory approval in the Kingdom of Saudi Arabia paves the way for Eroxon to improve the lives of ED patients in this key market

- James Barder, CEO of Futura

Futura is establishing a growing network of licencing and distribution partners and continues to strengthen its position, with regulatory approval having now been granted in six Middle Eastern countries, including the Kingdom of Saudi Arabia and the United Arab Emirates. Regulatory approval in the Kingdom of Saudi Arabia closely follows Futura's recent European and UK launch of Eroxon and the FDA's approval of MED3000 in the USA as the first clinically proven gel for the treatment of ED available without a doctor's prescription.

James Barder, CEO of Futura said: "Regulatory approval in the Kingdom of Saudi Arabia paves the way for Eroxon to improve the lives of ED patients in this key market. Eroxon is a game changer in the ED space with its rapid speed of onset helping men get an erection within 10 minutes. This approval comes at a pivotal time for the company, as we continue to grow and expand the availability of MED3000 globally by building out our licensing and distribution network."

  • Companies:
  • Futura Medical
See more

You may also like

Distribution

Futura expands partnership with M8 Pharmaceuticals for remainder of Central and South American region

Read more
Futura Medical is pleased to announce that M8 Pharmaceuticals has taken up its rights to extend its licensing agreement from Brazil and Mexico to market MED3000 in a further 14 countries throughout the Central and South American region

Trending Articles

  1. Navigating regulatory challenges in pharmaceutical packaging: lessons from the past and strategies for the future To safeguard drug efficacy, maintain strict quality standards and ensure patient safety, pharmaceutical packaging is subject to a wide range of regulations around the world, reports Kun Shing Chan, Director of QA at Tjoapack
  2. IMA Life and RheaVita team up to commercialise continuous biopharmaceutical freeze-drying tech The companies will work in tandem to develop and commercialise its continuous freeze-drying technology, allowing the rapid production of complex biopharmaceuticals
  3. IMed supports K2 medical systems in their EU MDR transition Consultancy firm helps K2 navigate the complex regulatory process to achieve Article 97 compliance
  4. Sanofi invests €40m into biopharmaceutical manufacturing at its Lyon Gerland site The pharma giant has expanded its French monoclonal antibody production capabilities, while also dedicating €25m to the development of a second-gen polyclonal antibody

Upcoming event

CPhI India

26–28 November 2024 | Online Conference & Networking | Delhi, India See all

You may also like

Distribution

Futura expands partnership with M8 Pharmaceuticals for remainder of Central and South American region

Futura Medical is pleased to announce that M8 Pharmaceuticals has taken up its rights to extend its licensing agreement from Brazil and Mexico to market MED3000 in a further 14 countries throughout the Central and South American region
Manufacturing

Abzena adds cell-based potency testing to its UK and US analytical service offering

The CDMO and CRO will now be able to develop GMP cell-based potency assays, which are crucial in measuring biopharmaceutical activity
Manufacturing

IMed Consultancy helps Toby Orthopaedics navigate UK regulations

Regulatory consultancy ensures compliance and confidence for Miami-based company
Manufacturing

Ardena's Oss nanomedicine facility gains full GMP approval from the Dutch Healthcare Authority

The pharmaceutical manufacturing facility can produce advanced nanoparticle drug delivery systems, including lipid-based, polymeric and metal oxide nanoparticles
Regulatory

Pfizer gains European Commission approval for haemophilia A and B drug, Hympavzi

The subcutaneous therapeutic is the first and only anti-tissue factor pathway inhibitor approved for the treatment of haemophilia A or B, and is available in an auto-injector format
Manufacturing

Pharmaceutics International bolsters its prefilled syringe production capabilities

The aseptic and oral dosage CDMO has invested USD $3.6m into advanced labelling, fill/finish and automated visual inspection technologies at its Hunt Valley site in Maryland, US
Manufacturing

Sanofi invests €40m into biopharmaceutical manufacturing at its Lyon Gerland site

The pharma giant has expanded its French monoclonal antibody production capabilities, while also dedicating €25m to the development of a second-gen polyclonal antibody
Subscribe now